Skip to main content
. 2015 Nov 5;5:15832. doi: 10.1038/srep15832

Table 1. 66 common significantly altered genes comparing tumour vs normal samples in the study cohort, our second cohort and the TCGA cohort.

Transcript ID Study cohort
Second cohort
TCGA
Fold-Change(yes vs. TNBC normal) p-value(TNBC status) Fold-Change(IDC vs. NAT) p-value(TvN) Fold-Change(IDC vs. NAT) p-value(TvN)
ABCA10 −3.07 3.59E–21 −4.69 1.76E–09 −2.71 5.51E–10
ABCA6 −8.96 5.42E–23 −5.01 6.37E–06 −3.83 4.95E–10
ABCA8 −20.18 5.12E–29 −5.41 7.23E–05 −2.58 6.91E–10
ABCA9 −15.16 2.85E–35 −4.55 2.43E–06 −2.54 4.50E–08
AGR2 −13.79 5.62E–49 −20.16 3.97E–05 −2.10 3.56E–06
ANKRD30A −31.96 1.48E–25 −43.09 5.71E–12 −4.91 9.08E–12
ANKRD30B −11.36 1.11E–17 −13.74 0.000141 −2.24 0.000458
ANLN 8.94 2.52E–56 15.88 2.62E–08 2.56 9.26E–06
ANP32E 3.06 5.47E–40 2.58 2.37E–06 2.05 0.000932
APOD −5.16 1.65E–16 −4.71 0.002127 −7.77 9.23E–09
AREG −16.35 1.54E–12 −7.97 0.000308 −2.06 2.80E–06
ASPM 19.80 2.17E–71 15.69 5.15E–08 2.97 4.08E–07
ATAD2 3.95 3.05E–32 2.93 0.002838 2.63 2.13E–06
BGN 3.38 1.20E–42 8.53 1.04E–05 2.48 1.21E–05
CALU 3.26 1.72E–27 2.86 3.88E–08 2.19 3.88E–06
CCT3 2.46 2.70E–42 2.39 1.16E–07 2.09 3.04E–06
CENPF 18.38 9.29E–69 14.06 1.36E–08 2.94 6.16E–08
CHML 2.58 1.22E–19 3.72 1.11E–05 2.12 2.98E–05
CKS2 5.13 3.45E–56 4.93 2.83E–05 4.20 6.45E–08
COL14A1 −5.57 4.10E–14 −3.01 0.000568 −3.44 5.00E–09
CXCL10 3.09 8.20E–33 24.83 6.19E–06 4.48 1.19E–05
CXCL11 9.68 9.14E–31 11.91 0.000101 2.03 6.14E–05
CXCL9 3.20 6.32E–17 6.31 0.005079 5.14 1.96E–05
DSC2 5.31 1.63E–29 1.89 0.006364 2.38 0.0009
ECT2 4.47 2.82E–34 3.38 0.000117 2.52 4.48E–07
EGR1 −12.87 8.24E–38 −4.73 5.73E–05 −3.08 9.70E–07
FGF10 −10.16 5.14E–16 −3.04 3.45E–05 −2.34 7.78E–11
FN1 4.73 3.88E–48 7.90 2.21E–12 3.94 1.26E–06
FREM1 −13.48 2.05E–36 −2.37 7.86E–06 −2.18 9.51E–09
GPI 1.87 3.91E–09 3.66 0.000226 2.23 9.43E–06
HIST1H2BD 2.60 1.71E–32 2.30 0.004616 2.47 0.00052
HIST1H3F 2.65 1.06E–38 1.61 0.002149 4.64 8.42E–07
IGF1 −5.83 1.42E–18 −3.65 0.000782 −2.96 1.21E–08
IL6ST −3.20 1.92E–23 −3.39 8.60E–08 −2.36 7.53E–06
INHBA 5.23 3.52E–60 7.48 1.49E–06 2.12 3.42E–06
JAM2 −4.20 2.88E–29 −2.47 0.001 −2.08 6.94E–08
KIF11 6.69 6.47E–60 8.69 1.39E–05 2.40 1.92E–06
KPNA2 3.72 6.80E–37 5.28 4.32E–08 2.16 9.43E–05
LAMA2 −4.28 4.96E–14 −2.51 0.001598 −2.02 7.43E–07
LIFR −7.78 1.84E–43 −5.28 0.000688 −2.67 3.25E–07
MEG3 −3.39 3.52E–68 −1.66 0.003507 −2.53 6.64E–09
MELK 14.34 1.72E–61 14.49 1.27E–07 2.13 2.71E–05
MKI67 14.02 1.35E–51 10.94 5.24E–08 2.18 9.96E–06
MME −8.64 6.89E–40 −5.17 0.001052 −2.08 6.00E–05
MYBL1 5.34 8.72E–17 4.34 0.005911 2.24 0.000728
NUSAP1 6.35 3.64E–46 8.42 1.55E–06 2.14 7.03E–07
OGN −58.54 4.14E–32 −5.26 5.37E–05 −4.13 7.52E–11
PDK4 −15.78 4.50E–36 −3.74 0.006427 −2.53 0.0019
PRDX1 1.91 8.91E–14 1.92 0.001102 2.00 2.67E–05
PRR11 2.52 2.88E–17 9.50 1.28E–08 2.30 1.58E–06
RAD51AP1 4.44 1.47E–29 4.30 0.00132 2.20 7.80E–06
RBMS3 −5.25 2.31E–35 −2.82 0.00085 −2.17 3.32E–07
SLC7A5 3.96 2.13E–32 2.25 0.000817 2.09 0.002088
SMC4 3.15 1.08E–37 2.70 7.86E–05 2.01 1.56E–05
SNRPD1 1.91 2.42E–26 2.39 0.000965 2.06 0.000118
SPARCL1 −2.16 2.33E–13 −1.93 0.001856 −2.65 9.09E–06
SPP1 6.68 2.97E–12 11.48 4.91E–06 3.40 2.30E–06
STIL 9.28 1.33E–38 4.23 9.29E–05 2.14 7.21E–06
SULF1 2.95 9.23E–24 5.76 2.21E–07 3.38 7.50E–08
TAT −3.68 3.73E–15 −60.22 2.49E–09 −2.27 6.83E–06
TBC1D9 −7.35 7.69E–50 −4.12 2.20E–07 −2.25 1.37E–07
TOP2A 8.58 4.63E–44 15.44 4.91E–10 4.13 6.26E–08
TPX2 11.10 2.56E–63 11.83 2.71E–09 3.57 6.46E–08
TSHZ2 −3.71 3.89E–20 −4.92 3.56E–05 −2.28 2.10E–06
UBE2C 19.93 8.26E–57 2.60 0.000417 2.22 1.53E–07
UBE2T 6.22 5.05E–47 8.55 1.24E–07 2.18 2.82E–05

The 4 TNBC specific genes are written in bold.